Jianshi Technology-B (09877) expects mid-term revenue to increase 385% to 400% year over year

According to the Zhitong Finance App, Jianshi Technology-B (09877) announced that the Group expects to achieve revenue of about RMB 63 million to RMB 65 million for the six months ending June 30, 2026, an increase of 385% to 400% over the previous year. Other revenue and revenue is approximately RMB 9 million to RMB 11 million, totaling approximately RMB 72 million to RMB 76 million. Compared with the same period last year, it will increase RMB 47 million to RMB 51 million, an increase of 188% to 204% over the previous year.

The main reasons for the increase in performance during the reporting period include: 1. The commercialization of the Group's transcatheter prosthetic aortic valve system Ken-Valve continued to achieve steady revenue growth. Ken-Valve can be applied to aortic valve reflux or concomitant stenosis. Its product design features and operational advantages enable the procedure to be quickly promoted and applied in multi-level medical institutions; 2. The Group actively carries out fee-based clinical implantation of various structural heart disease interventional products overseas. The good clinical results and application advantages of the product have been highly praised by key opinion leaders and experts around the world, and can meet the world's huge clinical needs for structural heart diseases that have not been met for a long time.

In addition, the Group will continue to promote the development of multiple innovative product pipelines and continue to deepen the international commercial layout to achieve rapid revenue growth; it will further improve management efficiency and reduce operating costs in production, supply chain, and operation management to achieve long-term development strategic goals.